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Deciphering and modulating G 
protein signalling in C. elegans 
using the DREADD technology
Simone Prömel, Franziska Fiedler, Claudia Binder, Jana Winkler, Torsten Schöneberg & 
Doreen Thor
G-protein signalling is an evolutionary conserved concept highlighting its fundamental impact on 
developmental and functional processes. Studies on the effects of G protein signals on tissues as well as 
an entire organism are often conducted in Caenorhabditis elegans. To understand and control dynamics 
and kinetics of the processes involved, pharmacological modulation of specific G protein pathways 
would be advantageous, but is difficult due to a lack in accessibility and regulation. To provide this 
option, we designed G protein-coupled receptor-based designer receptors (DREADDs) for C. elegans. 
Initially described in mammalian systems, these modified muscarinic acetylcholine receptors are 
activated by the inert drug clozapine-N-oxide, but not by their endogenous agonists. We report a novel 
C. elegans-specific DREADD, functionally expressed and specifically activating Gq-protein signalling 
in vitro and in vivo which we used for modulating mating behaviour. Therefore, this novel designer 
receptor demonstrates the possibility to pharmacologically control physiological functions in C. 
elegans.
Designer receptors exclusively activated by designer drugs (DREADDs) have been developed as a tool to study 
and to specifically manipulate G-protein signalling in vivo1,2. This technology for the selective control of sig-
nalling cascades has been found to be invaluable not only to investigate the impact of specific G-protein sig-
nalling on distinct physiological processes but also to control cellular functions in a cell-type specific manner. 
Besides DREADDs as pharmacogenetic tools also optogenetic methods have been generated. Both approaches 
are non-invasive and based on modified receptors which can be specifically activated – DREADDs exclusively by 
synthetic ligands and optogenetic tools only by light.
The first generation of DREADDs was based on muscarinic acetylcholine receptors which have been altered 
by two point mutations within transmembrane domains 3 and 5 to inhibit activation by the endogenous agonist 
acetylcholine (ACh) but allowing stimulation by the inert compound clozapine-N-oxide (CNO)1. Further 
modification allowed for specific activation of Gq, Gs, or Gi signalling pathways, respectively2. These DREADDs are 
called rM3Dq, rM3Ds, and hM4Di by convention3. They have been extensively pharmacologically characterized4 
and widely used to specifically activate and inactivate for instance neuron populations in vivo by employing the 
Gq- and the Gi-specific DREADDs, respectively5. DREADDs have also been involved to study neuronal impact 
on fear memory, Parkinson disease, Down syndrome, and the role of glial cells in vivo6–9. In the periphery, the 
DREADD technology has been applied to study metabolic functions in islet β -cells and hepatocytes2,10.
Despite the power and simplicity in the use of DREADDs many physiological processes and functions 
associated with specific signalling cascades are not easy to delineate in mammals due to the complexity of the 
organisms. The application in less complex systems would be highly advantageous to overcome these limita-
tions. Recently, the DREADD technology was transferred to Drosophila melangoster showing that mammalian 
DREADDs can be efficiently expressed in the fruitfly and modulate physiological functions linked to G-protein 
pathways11. The use of mammalian DREADDs in other organisms also raises the interesting question whether 
organism-specific DREADDs can be generated likewise. The nematode Caenorhabditis elegans, a very simple 
model organism frequently employed for the investigation of various biological questions, is highly suitable for 
the dissection of the impact of signalling cascades. So far only optogenetics have been successfully utilised as a 
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tool for the manipulation of some signalling cascades in the nematode12–14. However, G protein-signalling path-
ways are not well addressed by non-genetic tools.
Here, we show that the DREADD technology can be applied in C. elegans using a newly designed DREADD 
based on the nematode muscarinic receptor GAR-3b. In-depth pharmacological characterisation in vitro revealed 
that the DREADD specifically activates Gq signalling. In the nematode the DREADD is able to modulate physio-
logical functions upon stimulation with CNO in vivo.
Results
Mammalian DREADDs are not active in C. elegans. One prerequisite for the use of DREADDs in 
C. elegans is that the synthetic ligand CNO utilised to activate these receptors does not have any adverse effects 
on nematodes. To elucidate the influence the compound has on C. elegans fertility, development, viability, and 
the neuronal system as well as certain aspects of behaviour we treated wild-type nematodes in liquid culture 
with varying concentrations of CNO and assayed brood size, individuals reaching adulthood, lifespan, locomo-
tion, pharyngeal pumping, egg laying and sensitivity to aldicarb. However, none of the parameters was affected 
(Supplementary Fig. 1) indicating that the compound does not have any major side effects on C. elegans.
As mammalian DREADDs have been shown to be a useful tool for analyses in Drosophila, suggesting that they 
are able to activate distinct G-protein cascades in vertebrates and invertebrates likewise11, we tested these receptors 
in C. elegans. To investigate the functionality of mammalian DREADDs in the nematode, systems are required in 
which the physiological implications of Gs, Gq, and Gi protein-mediated pathways, respectively, are well understood. 
Protraction of copulatory spicules from the tail of the male nematode is dependent on a Gq signalling cascade15,16 and 
thus, offers one suitable read-out. Spicule protraction occurs during mating when the spicule is inserted into the her-
maphrodite’s vulva (Fig. 1A)15,17. The C. elegans homolog of the muscarinic acetylcholine receptor M3, GAR-3, is a G 
protein-coupled receptor (GPCR) involved in controlling this process. GAR-3 has been shown to activate a Gq cascade 
similar to its mammalian homolog18–20 and even triggers G-protein signalling in mammalian cells20 indicating that this 
Figure 1. The mammalian rM3Dq DREADD and rM3R are not functional in spicule protraction, as a model 
for DREADD activation in C. elegans. (A–D) Schematic representation of spicule protraction and theoretical 
model of GAR-3 and DREADD activation in this context, that all DREADD characterisations are based on  
(see Figs 1E and 4F). (A) GAR-3 mediates a Gq-protein signal which is involved in spicule protraction of the 
male nematode during mating culminating in insertion of the spicule into the hermaphrodite’s vulva. (B) GAR-3 
can be activated by Oxo M and CCh to induce spicule protraction involving the Gq protein-signalling cascade. 
This effect is independent of the presence of a hermaphrodite. (C) In the absence of GAR-3 neither Oxo M nor 
CCh trigger spicule protraction. (D) DREADDs activating the Gq protein-signalling cascade specifically trigger 
spicule protraction upon stimulation with CNO, but not with Oxo M or CCh. Such DREADDs can be rM3Dq 
or a C. elegans-specific DREADD (cegar-3Dq) in gar-3-deficient males. (E) Protraction rate in male nematodes 
containing mammalian DREADD constructs. Males were incubated with 100 mM Oxo M, 10 mM CCh, 2 mM 
CNO or H2O as negative control. Subsequently, spicule protraction was scored and protraction rates calculated 
in respect to the total male count. Wild-type worms (pha-1(e2123); him-5 (e1490)), gar-3 (pha-1(e2123); him-5 
(e1490) gar-3(gk305)) and transgenic gar-3; Ex[gar-3(+ )] males served as controls. Data are shown as mean ± SD. 
* * * p < 0.001; n ≥ 250. Indicated below each set of columns is the schematic model related to the respective data.
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receptor/Gq-protein cascade is evolutionary well preserved. Thus, we speculated that the DREADD (rM3Dq) which 
is based on the rat M3 receptor (rM3R) can activate Gq signalling in the nematode. The C. elegans strain null for gar-3, 
gar-3(gk305) displayed a spicule protraction defect (Fig. 1C,E Supplementary Tab. 1A) which was in concordance 
with previous studies16. It has been shown that carbachol (CCh) and oxotremorine M (Oxo M) activate GAR-316,21  
and thus, induced spicule protraction in wild-type males (Oxo M 82.5 ± 3.3%; CCh 84.7 ± 7.8%), independently of 
a hermaphrodite being present (Fig. 1B,E). Consistently, we did not observe this effect in gar-3(gk305) mutants (Oxo 
M 10.6 ± 4.7%; CCh 12.8 ± 2.4%) (Fig. 1C,E, Supplementary Tab. 1A). We tested whether Gq signalling induced by 
rM3Dq signalling rescues this defect by expressing the DREADD rM3Dq under the control of the gar-3 promoter in 
the gar-3 null background and stimulating the nematodes with CNO. However, we were unable to obtain any rescue 
(15.1 ± 5.1%) (Fig. 1E, Supplementary Tab. 1A). The same effect was seen in transgenic lines using the unmodi-
fied rM3R driven by the gar-3 promoter (Oxo M 14.0 ± 4.0%; CCh 13.2 ± 5.4%) (Fig. 1E, Supplementary Tab. 1A). 
Due to this lack of functionality we investigated expression of the yfp-tagged receptors by using fluorescent imaging 
techniques. However, we were unable to detect any protein (Supplementary Fig. 2) despite obtaining several trans-
genic lines containing receptor DNA (Supplementary Tab. 2). Likewise, no expression was observed for the other two 
mammalian DREADDs for Gs-protein signalling (rM3Ds) and for Gi-protein signalling (hM4Di) (data not shown).
Therefore, we conclude that the lack of activity of mammalian DREADDs in C. elegans is likely due to difficul-
ties in properly expressing or processing the receptors.
Generation of a C. elegans-specific DREADD. Since mammalian DREADDs did not seem to be 
properly expressed in C. elegans, we set out to generate a nematode-specific DREADD for modulation of G 
protein-signalling pathways in the worm. We sought to base this modified receptor on a muscarinic acetylcho-
line receptor similar to the mammalian DREADDs. Three G protein-linked acetylcholine receptor genes are 
known in C. elegans (gar-1, gar-2, gar-3) with GAR-2 being described to bind Gi/Go proteins and GAR-3 being a 
Gq-coupling receptor21,22. However, GAR-1 and GAR-2 differ in their pharmacological properties from mamma-
lian muscarinic acetylcholine receptors21,23,24, whereas GAR-3 is pharmacologically very similar to mammalian 
M3R and activates the Gq signalling cascade upon stimulation with ACh or CCh19–21. Further, alignment analyses 
revealed an overall amino acid sequence identity of GAR-3 to rM3R of 32.8%. Two splice variants, GAR-3a and 
GAR-3b, have been described with GAR-3b being the predominantly occurring form. The two isoforms only 
differ in 26 amino acid length within the 3rd intracellular loop (ICL)25. Also, amino acids Y3.33 and A5.46 (uni-
versal amino acid numbering system26), which are widely conserved among muscarinic acetylcholine receptors, 
are also present in the C. elegans GAR-3b (Fig. 2A), but only Y3.33 is conserved in C. elegans GAR-2 (Fig. 2B). 
Therefore, we chose GAR-3b for generation of a C. elegans-specific DREADD and – analogously to mammalian 
DREADDs – mutated amino acids Y3.33 (Y146C) and A5.46 (A237G). The DREADD was N-terminally tagged 
with an HA-epitope to allow for detection using commercially available antibodies.
Pharmacological characterisation of ceGAR-3Dq. The modified GAR-3b was pharmacologically 
characterized in respect to agonist and coupling specificity. Due to the high conservation of the three major G 
proteins Gq, Gi, and Gs among metazoan species analyses of functional G protein-coupling of receptors from 
C. elegans or other invertebrate species can be performed using mammalian systems27–29 with the results being 
transferable to the original system. Thus, we used transiently transfected COS-7 cells, as DREADD cell surface 
expression was highest compared to CHO-K1 and HEK-293GT cells (Supplementary Fig. 3A). Utilising label-free 
dynamic mass redistribution (DMR) experiments, we demonstrated that GAR-3b is only activated by CCh (Fig. 3A) 
whereas the receptor mutant (ceGAR-3Dq) is indeed a DREADD solely activated by the inert drug CNO but not 
by the muscarinic agonist CCh (Fig. 3B). CNO activated the DREADD in a concentration-dependent manner with 
an EC50 value of 3.5 μ M, whereas the muscarinic agonist CCh did not have an effect on receptor activity (Fig. 3C). 
To analyse the coupling specificity, further experiments involved detection of second messengers such as inositol 
phosphate (IP) as a read out for receptor activation. Consistent with the DMR measurements IP accumulation assays 
showed an increase in IP formation upon CCh stimulation of GAR-3b but not upon CNO treatment (Fig. 3D). 
In contrast, DREADD-mediated IP formation occurs only after stimulation with CNO. Further, measurement of 
calcium release also demonstrates the concentration-dependent activation of the DREADD-receptor upon CNO 
treatment (Fig. 3E), whereas GAR-3b is only activated by CCh (Fig. 3F). Neither of these compounds has any effect 
on mock-transfected cells demonstrating the receptor-specificity (Supplementary Fig. 3B).
This is consistent with previous studies where GAR-3-transfected CHO-K1 cells were shown to accumulate 
inositol phosphates and release Ca2+ upon CCh treatment19,21,25,30. Further, these elevated Ca2+ levels have 
been shown to stimulate cAMP production independent of Gs protein-signalling20. Also, it was demonstrated 
that GAR-3 is linked to Gi–protein coupling in cell culture experiments20,25. Thus, we tested for potential 
Gs- or Gi-protein coupling. Firstly, we applied second messenger assays to measure cAMP accumulation with 
and without pre-incubation of the adenylyl cyclase stimulator forskolin. Neither stimulation of GAR-3b nor of 
ceGAR-3Dq resulted in a change of cAMP accumulation (Supplementary Fig. 4A,B). However, it has to be 
noted that expression levels of GAR-3b and ceGAR-3Dq were rather low. Therefore, the lack in identifying 
Ca2+-mediated cAMP formation might be due to a lack of sensitivity. In fact, in a more sensitive CRE-based 
reporter gene assay an increase of cAMP was observed (Supplementary Fig. 4C,D). The EC50 values are similar to 
those obtained in DMR measurements (CNO at ceCAR-3Dq: 1.6 μ M; CCh at GAR-3b: 4.9 μ M) (Supplementary 
Tab. 3). For further validation of the G protein-coupling properties of GAR-3b, DMR measurements were 
performed with pertussis and cholera toxin to test for coupling to other G protein-signalling pathways. 
Neither cholera toxin nor pertussin toxin, a strong inhibitor of Gi-protein signalling31, altered signalling on 
CCh-stimulated GAR-3b transfected cells suggesting no involvement of toxin-sensitive Gs- or Gi-protein 
pathways (Supplementary Fig. 4F,G). These results indicate exclusive Gq–protein coupling of the DREADD and 
according to the suggested nomenclature the DREADD was therefore named ceGAR-3Dq3.
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Gq-protein signalling triggered by ceGAR-3Dq modulates spicule protraction behaviour in male 
nematodes. We next tested the applicability of the GAR-3-based DREADD ceGAR-3Dq in vivo. To ensure 
that the receptor is functional we first assessed expression of ceGAR-3Dq::yfp based on genomic gar-3 driven by 
the gar-3 promoter which is indistinguishable from gar-3::yfp, albeit appearing to be generally weaker (Fig. 4A–E). 
Subsequently, the capability of the DREADD to activate a Gq protein-signalling cascade when stimulated 
with CNO was investigated by quantifying spicule protraction movements (see Fig. 1D). Transgenic gar-3 
(gk305);Ex[cegar-3Dq] nematodes displayed no spicule protraction upon treatment with Oxo M or CCh (Oxo M 
17.9 ± 11.5%; CCh 13.6 ± 4.8%) similar to the effect seen in untreated males (16.8 ± 2.1%) (Figs 1B–D and 4F, 
Supplementary Tab. 1B), indicating that the DREADD is not activated by GAR-3 muscarinic agonists. However, 
spicule protraction was triggered upon stimulation with the synthetic DREADD agonist CNO (37.4 ± 6.3%) 
(Figs 1D and 4F, Supplementary Tab. 1B). These data are consistent with the pharmacological analyses in vitro 
showing that ceGAR-3Dq is a DREADD. To optimise the observed effect of ceGAR-3Dq-activated Gq-protein 
signalling on spicule protraction, a dose-response curve using increasing concentrations of CNO was conducted 
(Fig. 4G). However, due to the limited solubility of the compound, a maximal concentration of 2 mM CNO was 
tested. Unfortunately, stimulation did not reach saturation and thus, we were unable to determine an EC50 value. 
Approximately 40% of males protracted their spicules at this concentration. Activation of the DREADD and thus, 
spicule protraction was already detected 2 minutes after start of CNO treatment. Treatment duration did not have 
any influence on the extent of spicule protraction (Fig. 4H).
We next asked whether DREADD activation can be temporally controlled. Upon removal of gar-3(gk305);Ex 
[cegar-3Dq] nematodes from CNO the spicule protraction rate decreased over time (Fig. 4I). Approximately 
30 minutes post drug withdrawal spicule protraction reached the same level as observed in untreated controls, 
suggesting that DREADD activation is reversible. These results indicate that ceGAR-3Dq can be specifically acti-
vated by CNO in vivo and is able to mediate a Gq-protein signalling cascade. This activation can be temporally 
controlled.
Figure 2. Amino acid alignment of transmembrane domains 3 and 5 of muscarinic acetylcholine receptor 
orthologs. (A) Sequences of mAChR type 3 from 13 different species were retrieved from publically available 
databases such as NCBI/GenBank. Alignment was performed using the Clustal W alignment48. Shown is the 
amino acid sequence of transmembrane domain 3 and 5. Conserved residues are shaded in blue. Highlighted in 
red are the highly conserved tyrosine Y3.33 (Y146) and alanine A5.46 (A237) which are mutated in mammalian 
DREADDs. (B) Analogously, alignment of mAChR type 2 was performed. While Y3.33 is also conserved in C. 
elegans GAR-2, amino acid 5.46 differs from other muscarinic orthologs.
www.nature.com/scientificreports/
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Discussion
GPCRs are the largest family of cell surface receptors and the signals they mediate are involved in nearly all 
physiological functions32. Thus, gaining an in-depth understanding of their signalling modes and the ability to 
Figure 3. Pharmacological characterisation of ceGAR-3Dq. Agonist specificity was determined using dynamic 
mass redistribution. (A) GAR-3b is stimulated by 100 μ M CCh, whereas 10 μ M CNO does not stimulate the receptor. 
(B) 100 μ M CCh cannot stimulate ceCAR-3b, but the DREADD is stimulated by 10 μ M CNO. (C) The DREADD 
agonist CNO activates ceGAR-3Dq in a concentration dependent manner whereas the muscarinic agonist CCh 
does not have an effect on receptor activity. Given are one of three representative experiments performed in 
triplicates. (D) Second messenger assays reveal Gq-protein coupling of GAR-3b and ceGAR-3Dq. Transfected cells 
were incubated with media (non-stimulated), 100 μ M CCh, or 10 μ M CNO. CCh-stimulation of GAR-3b leads to a 
robust increase in IP formation, but ceGAR-3Dq is only activated by CNO. Given is the mean ± SD of three to four 
independent experiments performed in triplicates. (E) Calcium release was measured in ceGAR-3Dq transfected 
cells after stimulation with CCh and CNO. While CCh does not trigger Calcium release, CNO results into a 
concentration-dependent Calcium release. (F) GAR-3b transfected cells release Calcium after stimulation with CCh 
but not CNO. Given is the mean ± SEM of three independent experiments performed in duplicates.
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Figure 4. Cegar-3Dq is functional upon stimulation with CNO in C. elegans. (A–D) Expression and protein 
localisation of cegar-3Dq::yfp is indistinguishable from gar-3::yfp, both driven by the gar-3 promoter. Expression 
was detected in the pharynx (A, B; 1./3. row: DIC, 2./4. row: fluorescent image) and in the male tail (C, D; 1./3. 
row: DIC, 2./4. row: fluorescent image). Localisation of the DREADD appears to be similar to the one of GAR-3. 
Scale bars = 10 μ m. (E) Analyses of expression levels by quantification of intensities reveals that cegar-3Dq::yfp 
expression is significantly weaker than gar-3 expression. For quantification, images of the pharynx from 
www.nature.com/scientificreports/
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specifically modulate the signalling pathways has been intensively studied. However, determining the impact 
of a single type of receptor and its signalling pathways in a distinct cell type or tissue is virtually impossible as 
a single receptor is usually present in more than one cell type and endogenous agonists activate more than one 
receptor33. For the same reasons it is problematic to modulate distinct signalling cascades in a specific cell type 
in order to alter or control cellular functions. To overcome those limitations pharmacogenetic techniques in 
the form of designer receptors have been developed1. These so-called DREADDs are only activated by the inert 
compound CNO but not by the endogenous ligand ACh and thus, are a valuable tool to specifically activate G 
protein-signalling pathways in vivo. Combining this technique with the use of simple model organisms would 
render a powerful tool for the investigation and control of cell-type specific signalling.
In the present study, we generated a DREADD for the nematode C. elegans based on the G protein-linked 
acetylcholine receptor gar-3. This DREADD couples to the Gq protein-signalling cascade similar to GAR-321 and 
is activated exclusively by CNO. As a proof of principle, we provide functional data that the DREADD can be 
employed for spatiotemporal control of signalling in the nematode.
The DREADD technology is highly suitable for the use in the model organism C. elegans and genetically 
amenable so that DREADD constructs can be easily introduced. Further, we have shown that the synthetic com-
pound CNO which activates DREADDs can be administered by feeding or soaking nematodes without having 
any major detrimental effects.
Although expression of selected mammalian GPCRs in C. elegans has been shown to be generally possible 
for some receptors34, introduction of mammalian DREADDs rM3Dq, rM3Ds, and hM4Di as well as rM3R in 
the nematode did not render any functional receptors, despite their high sequence and functional conservation 
among various species. Our data indicate that these receptors are possibly not properly expressed in C. elegans. 
Several factors may contribute to this fact. As transgenic lines containing the receptors were obtained, a potential 
toxic effect of the constructs or their gene products can be ruled out. However, processing or membrane targeting 
of the mammalian proteins might be an issue. Alternatively, it is conceivable that certain co-factors or interaction 
partners required for functional expression are not present in C. elegans. Even though the codons of the mamma-
lian cDNA sequences were reviewed prior to construct generation and no overly problematic ones were identi-
fied, it cannot be excluded that non-optimal codon usage might account for this effect. It is, however, conceivable 
that these receptors are transcribed but not processed properly in nematode cells.
As the technology of mammalian DREADDs was not easily transferable to C. elegans, we sought to generate 
a nematode-specific one and have chosen the M3R homolog GAR-3. While the ceGAR-3Dq transgene used for 
the in vivo studies is based on the genomic locus of gar-3, cDNA of the predominantly occurring GAR-3b isoform 
was used for its initial pharmacological characterisation. This isoform does not differ from GAR-3a in its pharma-
cological properties, which is also similar to rat M3R where large parts of the 3rd intracellular loop can be deleted 
without changing receptor functionality35. In both cases we inserted two point mutations according to mamma-
lian DREADDs in transmembrane domains 3 and 5 of the receptor (Y146C/A237G in GAR-3) for generation of 
the novel DREADD. DMR measurements demonstrated that the modified GAR-3b is indeed a DREADD, only 
activated by CNO but not by the muscarinic agonist CCh (Fig. 3). The EC50 value for CNO activation determined 
in DMR measurements is 3.5 μ M (pEC50: 5.46 ± 0.43) which is about 100-fold higher than for the mammalian 
DREADD rM3Dq determined in yeast or cell culture experiments1,2,4,36.
This lower potency of CNO at the C. elegans DREADD is probably due to the lower potency of agonists at 
GAR-3b compared to rM3R (Supplementary Tab. 3). In vitro analyses of coupling properties of GAR-3b and 
ceGAR-3Dq revealed a robust Gq-mediated signalling with a Ca2+-dependent increase in cAMP37. Similar results 
have been obtained in previous studies19.
Although it cannot be easily proven that the GAR-3-based DREADD exclusively activates Gq signalling 
cascades especially as there are 21 Gα subunits in C. elegans with 17 being uncharacterized in regards to their 
signalling abilities as no clear homologs exist38,39, our functional assays point towards ceGAR-3Dq activating 
predominantly Gq signalling.
In vivo analyses revealed that the GAR-3b-derived DREADD ceGAR-3Dq is able to mediate a Gq-protein 
signalling cascade upon stimulation specifically with CNO but not with CCh or Oxo M. Activation of 
different cegar-3Dq::yfp expressing strains were taken and analysed in comparison with images from nematodes 
carrying gar-3::yfp. (F) Protraction rate in male nematodes containing the cegar-3Dq construct. Males were 
stimulated with 100 mM Oxo M, 10 mM CCh, 2 mM CNO or H2O as negative control. Subsequently, spicule 
protraction was scored. Wild-type worms (pha-1(e2123); him-5 (e1490)), gar-3 (pha-1(e2123); him-5 (e1490) 
gar-3(gk305)) and transgenic gar-3; Ex[gar-3(+ )] males served as controls. Data are shown as mean ± SD. 
n.s. not significant; * * p < 0.01; * * * p < 0.001; n ≥ 300. (G) Spicule protraction rates are dependent on the 
concentration of CNO. Male nematodes were incubated with the indicated concentrations of CNO and spicule 
protraction was scored subsequently. Nematodes deficient for gar-3 (pha-1(e2123); him-5 (e1490) gar-3(gk305)) 
served as negative control. Data are shown as mean ± SD, * * p < 0.01; * * * p < 0.001; n ≥ 200. Indicated below 
each set of columns is the schematic model related to the respective data. (H) Treatment duration does not 
have an effect on spicule protraction rate after 3 minutes. Male nematodes were incubated with 2 mM CNO and 
spicule protraction was scored. As negative control, nematodes deficient for gar-3 (pha-1(e2123); him-5 (e1490) 
gar-3(gk305)) were used. Data are shown as mean ± SD, * * p < 0.01; * * * p < 0.001; n ≥ 200. (I) The effect of 
DREADD activation is reversible. Transgenic gar-3; Ex[gar-3(+ )] males were stimulated with 2 mM CNO. After 
3 minutes the spicule protraction rate was determined (time point termed “0 minutes after CNO withdrawal”) 
and nematodes were withdrawn from the drug by transferring them into M9. Subsequently, spicule protraction 
was measured at distinct time points. Data are shown as mean ± SD, n ≥ 150.
www.nature.com/scientificreports/
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ceGAR-3Dq led to spicule protraction in males lacking gar-3 showing that the DREADD can complement the 
GAR-3-signalling cascade when activated. The detected effect is approximately 40% while 80% are achieved 
when re-introducing the gar-3 genomic sequence into gar-3-deficient nematodes and activating the receptor 
with CCh or Oxo M. Several factors may account for this reduced efficacy. Firstly, activation of both receptors 
occurs upon stimulation with different compounds. Although the EC50 values for both are within a similar range 
in vitro, nematodes were incubated in lower concentrations of CNO compared to Oxo M or CCh due to its lim-
ited solubility. Moreover, it is well possible that different drug uptake levels or limited drug accessibility of CNO 
can explain the observed differences in vivo. Obviously, this potential limitation in drug accessibility needs to be 
kept in mind when using DREADDs for applications in different types of tissue in C. elegans. Secondly, lower 
expression levels of the DREADD compared to gar-3 (Fig. 3) might also contribute to ceGAR-3Dq having a 
smaller effect on spicule protraction rate than GAR-3. However, despite these obvious limitations ceGAR-3Dq is 
useful for modulating Gq-protein signalling in C. elegans for certain applications.
The use of this novel ceGAR-3Dq in particular and DREADDs in general in the model organism C. elegans is 
highly advantageous for various applications. It can be employed for studying the impact of G-protein pathways 
in distinct cell-types or organs on the whole organism, an approach for which mammalian systems sometimes 
are too complex. Many cell-specific promoters have been described and offer a platform to express DREADDs 
in specific tissues. Further, it is highly suitable to manipulate the activity of certain cell types with neuroscience 
being one potential field of application. The neuronal network of C. elegans offers an ideal system for studies on 
neuronal networks and connectomes as it is well characterised. A hermaphrodite contains 302 neurons, which 
form about 7,000 chemical synapses40. Probing specific populations of neurons and stimulating or inhibiting 
their activity will help understanding neuronal networks and subsequently, for instance animal behaviour. So far, 
optogenetic tools have been employed to address these topics12,13. DREADDs are a powerful alternative to this 
technique as they allow for a dose-dependent modulation of signalling activity.
In summary, our results show that DREADDs are a functional tool in the nematode C. elegans. The newly 
designed nematode-specific DREADD ceGAR-3Dq based on the G protein-coupled acetylcholine receptor 
GAR-3 activates a Gq protein-signalling cascade and is able to modulate related pathways in vivo. This recep-
tor is exclusively stimulated by the inert compound CNO and thus, does not interfere with any physiological 
receptors. This pharmacogenetic toolbox now established in C. elegans offers a plethora of areas of applica-
tion. To fully explore the entire experimental potential of DREADDs in C. elegans future analyses will need to 
focus on the design of nematode DREADDs specific for activating other G protein cascades such as Gs and Gi 
protein-signalling pathways.
Methods
Materials. Carbamylcholine chloride (carbachol, CCh), Oxotremorine M (Oxo M), forskolin, 3-isobu-
tyl-1-methylxanthine (IBMX), aldicarb, and standard chemicals were purchased from Sigma Aldrich. 
Clozapine-N-Oxide (CNO) was obtained from the National Institutes of Health (Bethesda, MD) as part of 
the Rapid Access to Investigative Drug Program funded by the National Institute of Neurological Disorders 
and Stroke. Substances applied were dissolved in the media or buffer the according experiment was 
performed in.
Generation of plasmids and transgenes. GAR-3b constructs for in vitro assays were generated by clon-
ing gar-3b cDNA into the mammalian expression vector pcDNA5FRT and contained an N-terminal HA-tag 
which does not alter functional properties of GPCRs (pSP109)41. cegar-3Dq was engineered by introducing the 
two point mutations Y146C/A237G into pSP109 (pSP112). For generation of constructs for in vivo analyses 
recombineering was employed42,43. gar-3::yfp (genomic) inserted behind the gar-3 promoter (pYL9)16 was a kind 
gift from Dr. Rene Garcia, Texas A&M University. The construct containing the C. elegans-specific DREADD 
cegar-3Dq downstream the gar-3 promoter (pSP110) was generated by inserting the two point mutations (Y146C/
A237G) into the genomic sequence of gar-3 in the vector pYL9 (kind gift from Dr. Rene Garcia, Texas A&M 
University)16. Constructs comprising gar-3 promoter-driven mammalian DREADDs (pSP106, pSP108, pSP114) 
and rat M3R (pSP104) were cloned by exchanging gar-3 for the cDNA of the respective receptor in pYL9. For 
details see Supplementary Methods.
Cell culture. CHO-K1 and COS-7 cells were purchased from Leibniz Institute DSMZ – German Collection 
of Microorganisms and Cell Culture GmbH (CHO-K1: No. ACC 110, COS-7: No. ACC 60), HEK-GT cells were 
obtained from ThermoFisher Scientific (GripTite 293 MSR Cell Line, No. R79507). All cells were grown in F12 
media or Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin, and 100 μ g/ml streptomycin at 37 °C in a humidified incubator with 7% CO2. Lipofectamine 2000 (Life 
Technologies) was used for transient transfection according to the manufactures’ recommendations.
Dynamic mass redistribution. Dynamic mass redistribution measurements are a label free assay system 
to study GPCR properties in living cells44. Thus, COS-7 cells were seeded into T25 flask 16 to 24 hours prior to 
transfection with 3 μ g plasmid DNA and 7.5 μ l Lipofectamine. The next day, 6,000 cells were split into one well 
of an Epic 384-Well Fibronectin-Coated Microplate (Corning, Kaiserslautern, Germany). DMR measurements 
were carried out at a Corning Epic label-free detection platform. CCh and CNO were dissolved in HBSS buffer at 
different concentrations. For equilibration, cells incubated with HBSS buffer for 2 hours, followed by a baseline 
recording for 5 minutes. After adding CCh and CNO DMR was recorded for up to 75 minutes. To determine 
G protein-coupling specificity cells were incubated either with pertussis (100 ng/ml) or cholera toxin (1 μ g/ml) 
overnight prior to DMR recordings.
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IP accumulation assay. To measure inositol phosphate (IP) formation COS-7 cells were split into 12-well 
plates (1.5 × 105 cells/well) and transfected with a total amount of 0.5 μ g of plasmid DNA and 1.5 μ l Lipofectamine 
per well. Subsequently, cells were incubated with 2 μ Ci/ml of myo-3H-inositol (18.6 Ci/mmol, Perkin Elmer) for 
18 hours. Thereafter, cells were washed once with serum-free DMEM containing 10 mM LiCl followed by incu-
bation with test compounds for 30 minutes at 37 °C. Intracellular IP levels were determined by anion-exchange 
chromatography as described previously45.
Fluorometric Calcium measurements. COS-7 cells were split into T25-flasks (1.2 × 106) and transfected 
with 3 μ g plasmid DNA and 7.5 μ l Lipofectamine the next day. 48 hours past transfection, cells were detached 
using Versene and labelled in DMEM with 4 μ M Fluo-4 AM (Molecular probes) for 30 minutes at 37 °C. Free dye 
was removed by centrifugation, and cell suspensions were re-suspended into HBS buffer (132 mM NaCl, 10 mM 
HEPES, 6 mM KCl, 5.5 mM glucose, and 1 mM MgCl2, adjusted to pH 7.4 with NaOH). The cell suspension was 
dispensed into black, clear-bottom 384 microwell plates (Corning, Kaiserslautern, Germany) with 45.000 cells 
per well. Fluorescence measurements were performed in a two-step protocol using a fluorescence imaging plate 
reader and a robotic liquid handling station (Freedom Evo 150, Tecan, Männedorf, Switzerland). Fluorescence 
intensity was corrected for the background and normalized to the initial intensities (F/F0).
C. elegans strains. C. elegans strains were cultured and manipulated according to standard protocols46. 
Wild-type worms were C. elegans variety Bristol, N2 and grown at 22 °C. The allele gar-3(gk305) was generated 
by the C. elegans gene knockout consortium. The strain pha-1(e2123); him-5 (e1490) gar-3(gk305) was previously 
described (kind gift from Dr. Rene Garcia, Texas A&M University)16 and kept at 15 °C. The transgenes aprEx-
183[gar-3::yfp (pYL9) pha-1(+ ) pBSK], aprEx184[cegar-3Dq::yfp (pSP110) pha-1(+ ) pBSK], aprEx186[rM3R::yfp 
(pSP104) pha-1(+ ) pBSK], aprEx187[rM3Dq::yfp (pSP106) pha-1(+ )pBSK] aprEx188[rM3Ds::yfp (pSP108) pha-
1(+ ) pBSK] and aprEx189[hM4Di::yfp (pSP114) pha-1(+ ) pBSK] were generated for this study (for details see 
Supplementary Methods) and cultivated at 25 °C.
Spicule protraction assay. 24 hours prior to conducting the assay, wild-type L4 males were put separately 
onto NGM agar plates containing Escherichia coli OP50. Subsequently, males were mounted onto a 2% agarose 
pad and a 100 μ l of 2 mM CNO, 100 mM Oxo M, 10 mM CCh or H2O, respectively, were applied. Males were 
scored for spicule protraction using a Leica M165FC microscope.
Nematodes with spicules partially or fully protracted were scored positive. Protraction rates were calculated 
in relation to the total number of males investigated.
Microscopy. For analysis of transgene expression adult males were mounted in M9 containing 250 μ M 
levamisole onto a 2% agarose pad. Differential interference contrast (DIC) and confocal fluorescent images were 
collected with an Olympus Fluoview FV1000 setup. Fluorescence signals were quantified by intensity analysis 
using ImageJ software47.
Statistical analyses. Statistical significance of assay data from spicule protraction assays was determined 
using a Fisher’s exact test for each genotype and condition. For statistical analyses of brood size, individuals 
reaching adulthood, lifespan, locomotion, pharyngeal pumping, egg laying, sensitivity to aldicarb, and fluorescent 
intensity calculations a student’s t-test was performed.
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